Skip to content

Study · Systematic review · 2017

10 results

Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ

Diabetes, obesity & metabolism17 Feb 2017Cited by 334 (Europe PMC)

PMID27981757 (opens in a new tab)DOI10.1111/dom.12849 (opens in a new tab)PepBankPUB-27981757
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In people with type 2 diabetes, liraglutide reduced HbA1c by 0.45% more than twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c more than twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c versus twice-daily exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c difference
    0.45%
    liraglutide vs exenatide twice daily

    Source sentences

    Summary
    Compared with twice-daily exenatide, dulaglutide treatment was associated with the greatest HbA1c and FPG reduction (0.51% and 1.04 mmol/L, respectively), followed by liraglutide (0.45% and 0.93 mmol/L, respectively) and once-weekly exenatide (0.38% and 0.85 mmol/L, respectively); similar reductions…
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.
  2. 02HumanSystematic reviewEfficacy outcome

    In people with type 2 diabetes, liraglutide reduced fasting plasma glucose by 0.93 mmol/L more than twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood sugar more than twice-daily exenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose versus twice-daily exenatide
    Study

    n: not reported in source

    Comparator
    Exenatide twice daily
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Fasting plasma glucose difference
    0.93 mmol/L
    liraglutide vs exenatide twice daily

    Source sentences

    Summary
    Compared with twice-daily exenatide, dulaglutide treatment was associated with the greatest HbA1c and FPG reduction (0.51% and 1.04 mmol/L, respectively), followed by liraglutide (0.45% and 0.93 mmol/L, respectively) and once-weekly exenatide (0.38% and 0.85 mmol/L, respectively); similar reductions…
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.
  3. 03HumanSystematic reviewEfficacy outcome

    In people with type 2 diabetes, liraglutide reduced HbA1c more than lixisenatide, with reductions similar to those seen against twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c more than lixisenatide did.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c versus lixisenatide
    Study

    n: not reported in source

    Comparator
    Lixisenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    similar reductions were found when these 3 agents were compared with lixisenatide
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.
  4. 04HumanSystematic reviewEfficacy outcome

    In people with type 2 diabetes, liraglutide reduced fasting plasma glucose more than lixisenatide, with reductions similar to those seen against twice-daily exenatide.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered fasting blood sugar more than lixisenatide did.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose versus lixisenatide
    Study

    n: not reported in source

    Comparator
    Lixisenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    similar reductions were found when these 3 agents were compared with lixisenatide
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

Studies that did not test the peptide alone6

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists, including liraglutide, reduced HbA1c compared with placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs, including liraglutide, lowered HbA1c more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c versus placebo
    Study

    n = 14,464

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs reduced glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists, including liraglutide, reduced fasting plasma glucose compared with placebo.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs, including liraglutide, lowered fasting blood sugar more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting plasma glucose versus placebo
    Study

    n = 14,464

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs reduced glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG) levels
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists except albiglutide, including liraglutide, reduced weight compared with placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide and most other GLP-1 drugs reduced weight more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure.
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists except albiglutide, including liraglutide, increased the risk of hypoglycaemia compared with placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide and most other GLP-1 drugs raised the risk of low blood sugar compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseHypoglycaemia risk versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure.
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists except albiglutide, including liraglutide, increased the risk of gastrointestinal side effects compared with placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide and most other GLP-1 drugs raised the risk of stomach and gut side effects compared with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal side effects versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure.
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  6. 10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In people with type 2 diabetes, all GLP-1 receptor agonists except dulaglutide and taspoglutide, including liraglutide, reduced systolic blood pressure compared with placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide and most other GLP-1 drugs lowered systolic blood pressure more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseSystolic blood pressure versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    Compared with placebo, all GLP-1RAs except albiglutide reduced weight and increased the risk of hypoglycaemia and gastrointestinal side effects, and all agents except dulaglutide and taspoglutide reduced systolic blood pressure.
    1 context sentence
    Summary · context
    We electronically searched, up to June 3, 2016, published randomized clinical trials lasting between 24 and 32 weeks that compared a GLP-1RA (albiglutide, dulaglutide, twice-daily exenatide and once-weekly exenatide, liraglutide, lixisenatide, semaglutide and taspoglutide) with placebo or another GLP-1RA.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.